1. Clearmind announces a 1-for-40 reverse share split effective December 15, 2025. 2. This split aims to comply with Nasdaq Minimum Bid Price Rule. 3. Shares will reduce from approximately 60 million to about 1.5 million. 4. Company plans to enhance its patent portfolio and develop new therapeutics. 5. Forward-looking statements highlight uncertainty regarding Nasdaq compliance.
FAQ
Why Bearish?
Reverse splits often indicate previous price struggles and can signal investor concern; e.g., XYZ Corp facing compliance issues before a reverse split saw declining interest.
How important is it?
The reverse split is pivotal for compliance, affecting investor confidence and stock perception.
Why Short Term?
Initial negative sentiment typically follows reverse splits; short-term focus as market reassesses value.
Clearmind Medicine (CMND) Announces 1-for-40 Reverse Share Split
Vancouver, Canada – December 10, 2025
Overview of the Reverse Share Split
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company focused on developing innovative therapeutics derived from neuroplastogens, has announced a reverse share split of its common shares at a ratio of 1-for-40. This strategic move aims to help the company regain compliance with the Nasdaq Minimum Bid Price Rule and will take effect on December 15, 2025.
The reverse split was authorized by Clearmind's board of directors on November 12, 2025, in alignment with the company's articles of association.
Impact of the Reverse Share Split
- The number of issued and outstanding shares will decrease from 59,991,852 to 1,499,796, pending adjustments for fractional shares.
- No fractional shares will be issued; instead, all fractions will be rounded up to the nearest whole share.
- A proportional adjustment will be applied to the per-share exercise price and the total number of shares available through outstanding options and warrants.
About Clearmind Medicine Inc.
Clearmind is a pioneering pharmaceutical biotech company that specializes in the development of psychedelic-derived therapeutics targeting significant health issues, notably alcohol use disorder. The company is dedicated to researching and commercializing psychedelic compounds for use as regulated medicines, foods, or supplements.
Currently, Clearmind holds an intellectual property portfolio comprising nineteen patent families along with 31 granted patents. The company plans to continue expanding its patent holdings and is actively seeking additional intellectual property to enhance its offerings.
Trading Information
Shares of Clearmind Medicine are listed on the Nasdaq under the symbol CMND and also traded on the Frankfurt Stock Exchange as CWY0.
Contact Information
For further inquiries, please contact Clearmind's investor relations:
- Email: invest@clearmindmedicine.com
- Phone: (604) 260-1566
- U.S. Inquiries: CMND@crescendo-ir.com
- General Inquiries: info@clearmindmedicine.com
- Website: clearmindmedicine.com
Forward-Looking Statements
This article contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act. Terms like “expects,” “anticipates,” and similar phrases are used to indicate future events or outcomes.
While Clearmind anticipates that the reverse share split will help in meeting Nasdaq requirements, there can be no guarantee regarding the company's continued listing on the Nasdaq Capital Market or the successful execution of this split.